Improvac

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Synthetic peptide analogue of GnRF conjugated to diptheria toxoid

Available from:

Zoetis Belgium SA

ATC code:

QI09AX

INN (International Name):

Gonadotropin releasing factor (GnRF) analogue-protein conjugate

Therapeutic group:

Male pigs (from 8 weeks of age); Female pigs (from 14 weeks of age)

Therapeutic area:

Imunologija za suidae

Therapeutic indications:

Male pigs:Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Drugi ključni dejavnik merjasca taint, skatole, se lahko tudi zmanjša kot posredni učinek. Agresiven in spolne (montaža) vedenje so zmanjšane tudi. Female pigs:Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Product summary:

Revision: 20

Authorization status:

Pooblaščeni

Authorization date:

2009-05-11

Patient Information leaflet

                                18
B. NAVODILO ZA UPORABO
19
NAVODILO ZA UPORABO
IMPROVAC RAZTOPINA ZA INJICIRANJE ZA PRAŠIČE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za
sproščanje serij:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Improvac raztopina za injiciranje za prašiče
3.
NAVEDBAUČINKOVIN(E) IN DRUGIH SESTAVIN
En odmerek (2 ml) vsebuje:
ZDRAVILNA UČINKOVINA:
Analog gonadotropin sproščajočega faktorja (GnRF) - konjugiran
protein
najmanj 300 µg.
(sintetični peptidni analog GnRF konjugiran na toksoid davice)
DODATEK:
Dietilaminoetil (DEAE)-dekstran, vodni, nemineralni, dodatek na oljni
osnovi
300 mg.
POMOŽNA SNOV:
klorokrezol
2 mg.
4.
INDIKACIJA(E)
Prašiči, samci:
Indukcija protiteles proti GnRF za dosego začasne imunološke
supresije funkcije testisov. Za uporabo
kot alternativa fizični kastraciji za zmanjšanje vonja po merjascu,
ki ga povzroča ključna sestavina
vonja po merjascu androstenon pri nekastriranem prašiču samcu, po
nastopu pubertete.
Druga ključna sestavina vonja po merjascu, skatol, se lahko zaradi
indirektnega učinka zniža.
Agresivno in spolno (zaskakovanje) vedenje je tudi zmanjšano.
Začetek imunosti (indukcija proti-GnRF protiteles) se lahko
pričakuje v enem tednu po drugem
cepljenju. Znižanje nivoja androstenona in skatola je bila dokazana
od 4 do 6 tednov po drugem
cepljenju. To odraža čas, ki je potreben za očiščenje sestavin
vonja po merjascu, ki so že prisotne v
času cepljenja kot tudi raznolikost odziva med posameznimi živalmi.
Zmanjšanje agresivnega in
spolnega (zaskakovanje) vedenja lahko pričakujemo od 1 do 2 tedna po
drugem cepljenju.
Svinje, samice:
Indukcija protiteles proti GnRF za dosego začasne imunološkega
zaviranja funkcije jajčnikov
(zaviranje estrusa) za zmanjšanje pojavnosti neželenih brejosti pri
mladicah, namenjenih za zakol,
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-04-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-04-2022
Public Assessment Report Public Assessment Report Bulgarian 05-04-2022
Patient Information leaflet Patient Information leaflet Spanish 05-04-2022
Public Assessment Report Public Assessment Report Spanish 05-04-2022
Patient Information leaflet Patient Information leaflet Czech 05-04-2022
Public Assessment Report Public Assessment Report Czech 05-04-2022
Patient Information leaflet Patient Information leaflet Danish 05-04-2022
Public Assessment Report Public Assessment Report Danish 05-04-2022
Patient Information leaflet Patient Information leaflet German 05-04-2022
Public Assessment Report Public Assessment Report German 05-04-2022
Patient Information leaflet Patient Information leaflet Estonian 05-04-2022
Public Assessment Report Public Assessment Report Estonian 05-04-2022
Patient Information leaflet Patient Information leaflet Greek 05-04-2022
Public Assessment Report Public Assessment Report Greek 05-04-2022
Patient Information leaflet Patient Information leaflet English 05-04-2022
Public Assessment Report Public Assessment Report English 05-04-2022
Patient Information leaflet Patient Information leaflet French 05-04-2022
Public Assessment Report Public Assessment Report French 05-04-2022
Patient Information leaflet Patient Information leaflet Italian 05-04-2022
Public Assessment Report Public Assessment Report Italian 05-04-2022
Patient Information leaflet Patient Information leaflet Latvian 05-04-2022
Public Assessment Report Public Assessment Report Latvian 05-04-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-04-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-04-2022
Public Assessment Report Public Assessment Report Lithuanian 05-04-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-04-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 05-04-2022
Public Assessment Report Public Assessment Report Hungarian 05-04-2022
Patient Information leaflet Patient Information leaflet Maltese 05-04-2022
Public Assessment Report Public Assessment Report Maltese 05-04-2022
Patient Information leaflet Patient Information leaflet Dutch 05-04-2022
Public Assessment Report Public Assessment Report Dutch 05-04-2022
Patient Information leaflet Patient Information leaflet Polish 05-04-2022
Public Assessment Report Public Assessment Report Polish 05-04-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-04-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 05-04-2022
Public Assessment Report Public Assessment Report Portuguese 05-04-2022
Patient Information leaflet Patient Information leaflet Romanian 05-04-2022
Public Assessment Report Public Assessment Report Romanian 05-04-2022
Patient Information leaflet Patient Information leaflet Slovak 05-04-2022
Public Assessment Report Public Assessment Report Slovak 05-04-2022
Patient Information leaflet Patient Information leaflet Finnish 05-04-2022
Public Assessment Report Public Assessment Report Finnish 05-04-2022
Patient Information leaflet Patient Information leaflet Swedish 05-04-2022
Public Assessment Report Public Assessment Report Swedish 05-04-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-04-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 05-04-2022
Patient Information leaflet Patient Information leaflet Icelandic 05-04-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 05-04-2022
Patient Information leaflet Patient Information leaflet Croatian 05-04-2022
Public Assessment Report Public Assessment Report Croatian 05-04-2022

View documents history